The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has been Reiterated to Buy by H.C. Wainwright in its latest research note that was published on August 13. IMGN has given a price target of $5 by H.C. Wainwright, with other Wall Street analysts also giving their reports regarding the stock. Guggenheim analysts have downgraded their rating of IMGN stock from Buy to Neutral in a separate flash note to investors on May 15. Analysts at H.C. Wainwright issued an upgrade fromNeutral to Buy for the stock, in a research note that dated back to May 06.
ImmunoGen, Inc., which has current market capitalization of above $483 Million, published its last quarter earnings on June 30, 2019.
IMGN surged by $0.02 during the normal trading session on Thursday and reaching a high of $3.25 during the day while it closed the day at $3.20. The ImmunoGen, stock had a low trading volume of 1.54 million shares on that day, which is low compared to the average daily volume of 2.51M shares. IMGN has also gained 11.89% of its value over the past 7 days. However, the stock has surged by 46.79% in the 3 months of the year. Over the past six months meanwhile, it has gained 18.52% while it has lost 33.33% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -1.54% from its 3 months high price. However, taking another look at IMGN will indicate that it is trading +76.8% away from its 90-day low. Looking at the bigger picture, the ImmunoGen, Inc. stock has dropped by -67.48% from its 52-week high while it has surged by +81.82% from its 52-week low price.
On January 07, 2019 Gregory Richard J., Executive VP & CSO sold 3038 shares of the company. The average price for that transaction was $5.27 per share, which meant that Gregory Richard J. earned $16010.26 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Director, Goldberg Mark Alan purchasing 30000 shares of this stock on November 06, 2018. The average purchasing price for the stock was $5.76 per share, with the purchased stock accruing $172800. Following this transaction, the Director Goldberg Mark Alan now holds 132769 shares of the company, which is worth around $428843.9.
ImmunoGen, has around 240 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $75 Billion. The ImmunoGen, stock is bringing in revenue of over 12 months, which is roughly 44 Billion. Despite all that, ImmunoGen, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 0.84%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 95.61%. This figure is better than the company’s 20-day Raw Stochastic average which currently stands at 93.42%. Over the past 20 days, ImmunoGen,’s Stochastic %K stood at 96.39% while its Stochastic %D was revealed to be 91.52%.